ComboMATCH will test new combinations of cancer drugs - NCI
The National Cancer Institute launched ComboMATCH, a precision medicine initiative testing drug combinations targeting specific tumor mutations. It aims to identify effective treatments for advanced clinical trials, involving both FDA-approved and investigational drugs. ComboMATCH includes phase 2 trials for adults and children, focusing on genomic abnormalities to improve treatment outcomes.
Related Clinical Trials
Reference News
The National Cancer Institute launched ComboMATCH, a precision medicine initiative testing drug combinations targeting specific tumor mutations. It aims to identify effective treatments for advanced clinical trials, involving both FDA-approved and investigational drugs. ComboMATCH includes phase 2 trials for adults and children, focusing on genomic abnormalities to improve treatment outcomes.